Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock (HTG775)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 March 2026
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock (HTG774)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 March 2026
VA ECMO for postcardiotomy cardiogenic shock in adults (HTG762)Product type:GuidanceProgramme:HealthTech guidancePublished: 18 December 2025
Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)Product type:GuidanceProgramme:HealthTech guidancePublished: 4 December 2025
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest (HTG765)Product type:GuidanceProgramme:HealthTech guidancePublished: 22 October 2025
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 17 April 2026Expected publication date: 7 May 2026
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)Status:In developmentProgramme:Health technology evaluationExpected publication date: 2 December 2026
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventionsStatus:Awaiting developmentProgramme:HealthTech guidanceExpected publication date: TBC
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Point-of-care lipid tests for cardiovascular disease prevention in primary and community careStatus:Awaiting developmentProgramme:HealthTech guidanceExpected publication date: TBC